Esophageal squamous cell carcinoma
Conditions
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion Criteria for Retrospective Cohort 1. Age = 18 years, any gender, expected survival = 1 year; 2. Patients who underwent esophageal ESD at Zhongshan Hospital affiliated with Fudan University or its partner centers between 2011.1.1 and 2024.7.31; 3. Final pathology showed esophageal squamous cell carcinoma without invasion beyond the submucosa (i.e., T1a and T1b); 4. Subjects voluntarily joined this study, provided verbal consent or signed informed consent, had good compliance, and cooperated with follow-up. Inclusion Criteria for Prospective Cohort 1. Age = 18 years, any gender, expected survival = 1 year; 2. Patients who underwent esophageal ESD at Zhongshan Hospital affiliated with Fudan University between 2025.3.1 and 2025.8.31; 3. Final pathology showed esophageal squamous cell carcinoma without invasion beyond the submucosa (i.e., T1a and T1b); 4. Subjects voluntarily joined this study, provided verbal consent or signed informed consent, had good compliance, and cooperated with follow-up.
Exclusion criteria
Exclusion criteria: Exclusion Criteria for Retrospective Cohort 1. Received neoadjuvant therapy before ESD; 2. Postoperative pathology showed adenocarcinoma or tumor invasion beyond the submucosa; 3. Patients with mental disorders or a history of psychiatric drug abuse; 4. Incomplete clinical data or lost to follow-up; 5. Other cases deemed unsuitable for inclusion by the attending physician. Exclusion Criteria for Prospective Cohort 1. Received neoadjuvant therapy before ESD; 2. Postoperative pathology showed adenocarcinoma or tumor invasion beyond the submucosa; 3. Patients with mental disorders or a history of psychiatric drug abuse; 4. Incomplete clinical data or lost to follow-up; 5. Other cases deemed unsuitable for inclusion by the attending physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of quality of life;Progression free survival;Incremental Cost-Effectiveness Ratio; | — |
Countries
China
Contacts
Public ContactPing-Hong Zhou
Zhongshan Hospital, Fudan University
Outcome results
None listed